# 2025-20768: FDA Tobacco Committee Meets: Comments Sought

2025-20768, Tobacco Products Scientific Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-11-24, effective 2026-01-22 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-20768
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-20768
- Title: Tobacco Products Scientific Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 52969
- Published: 2025-11-24
- Effective: 2026-01-22
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Tobacco Committee Meets: Comments Sought

## Summary

The FDA is hosting a public online meeting on January 22, 2026, where experts will discuss tobacco product rules and give advice. Anyone interested can share their thoughts by January 21, 2026, through a public comment system. This meeting affects tobacco companies, public health groups, and anyone curious about tobacco safety and regulations.

## Abstract

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Tobacco Products Scientific Advisory Committee (TPSAC or the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues related to tobacco products. The meeting will be open to the public. FDA is establishing a docket for public comments related to the TPSAC meeting.

## Effects PRIA read

- Public comment docket and deadlines: benefit, low. The FDA opened docket FDA-2025-N-0835 for public comments on the Tobacco Products Scientific Advisory Committee meeting. Electronic comments are accepted until 11:59 p.m. ET on January 21, 2026; comments received on or before January 7, 2026 will be provided to the Committee, while comments receive…
- Opportunity to give oral testimony: benefit, low. People who want to speak at the advisory committee must request to speak and submit a brief statement with names and contact information by 12:00 p.m. ET on December 31, 2025. Oral presentations are scheduled between about 1:00 p.m. and 2:00 p.m. ET on January 22, 2026, and FDA may run a lottery if…
- Meeting available online and captioned: benefit, low. The TPSAC meeting on January 22, 2026 (9:00 a.m. to 4:30 p.m. ET) will be held via an online video conferencing platform, will be captioned and recorded, and will be available at the provided YouTube live link on the day of the meeting. FDA intends to post background material no later than 2 busine…
- TPSAC will review ZYN MRTP applications: mixed, medium. On January 22, 2026, the Committee will discuss modified risk tobacco product applications submitted by Swedish Match USA, Inc. for a list of ZYN products (including Cool Mint, Peppermint, Spearmint, Wintergreen, Citrus, Coffee, Cinnamon, Smooth/Original, Chill/Classic, Menthol/Fresh in 3 mg and 6…
- Disability accommodations request window: benefit, low. FDA will make efforts to accommodate persons with disabilities at the advisory committee meeting; if you require accommodations, you must contact the designated FDA official at least 7 days before the meeting.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2025-20768 on federalregister.gov](https://www.federalregister.gov/documents/2025/11/24/2025-20768/tobacco-products-scientific-advisory-committee-notice-of-meeting-establishment-of-a-public-docket)
- [2025-20768 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-11-24/pdf/2025-20768.pdf)

## Related
- [Previous: 2025-20767, Intercept Pharmaceuticals, Inc., et al.; Withdrawal of Approval of New Drug App…](https://policyrisk.com/federal-register/2025-20767)
- [Next: 2025-20769, Request for Information for 2027 Department of Defense (DoD) State Policy Prior…](https://policyrisk.com/federal-register/2025-20769)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-20768 (as of 2026-06-08).